Sunitinib (SU 11248) 是一种多靶点受体酪氨酸激酶抑制剂，对 VEGFR2 和 PDGFRβ 的 IC50 值分别为 80 nM 和 2 nM。作为一种 ATP 竞争性抑制剂，舒尼替尼有效抑制 Ire1α 的自磷酸化，从而阻止 RNase 激活。

Axitinib是一种多靶点酪氨酸激酶抑制剂，对VEGFR1、VEGFR2、VEGFR3和PDGFRβ的IC50值分别为0.1 nM、0.2 nM、0.1-0.3 nM和1.6 nM。

Nintedanib（BIBF 1120）是一种强效的三重血管激酶抑制剂，对VEGFR1/2/3、FGFR1/2/3和PDGFRα/β的IC50值分别为34 nM、13 nM、13 nM、69 nM、37 nM、108 nM、59 nM和65 nM。

Crenolanib是一种强效且选择性的III类受体酪氨酸激酶FLT3和PDGFRα/β野生型和突变型异构体的抑制剂，Kd值分别为0.74 nM和2.1 nM/3.2 nM。

AZD2932是一种有效的多靶点激酶抑制剂，其对VEGFR2、PDGFβ、PDGFβ和PDGFβ的IC50值分别为8、4、7和9 nM。

Sorafenib is a multi-kinase inhibitor that inhibits Raf-1 and B-RAF (IC50s = 6 and 22 µM, respectively), as well as the receptor tyrosine kinases VEGFR2, VEGFR3, PDGFRβ, FLT3, and c-Kit (IC50s = 90, 15, 20, 57, and 58 nM, respectively).

Dovitinib is a multitargeted RTK inhibitor, mostly for class III (FLT3/c-Kit) with IC50 of 1 nM/2 nM, also potent to class IV (FGFR1/3) and class V (VEGFR1-4) RTKs with IC50 of 8-13 nM.

Linifanib is a potent ATP-competitive VEGFR/PDGFR inhibitor for KDR, CSF-1R, Flt-1/3 and PDGFRβ with IC50 of 4 nM, 3 nM, 3 nM/4 nM and 66 nM respectively.

Masitinib is an inhibitor for Kit and PDGFRα/β with IC50 of 200 nM and 540 nM/800 nM, weak inhibition to ABL and c-Fms.

Tivozanib is an inhibitor of VEGFR1, VEGFR2 and VEGFR3 with IC50s of 30 nM, 6.5 nM, 15 nM, respectively. It can also inhibit PDGFR and c-Kit.

TSU-68 is a multiple receptor tyrosine kinase inhibitor with IC50 of 2.1 μM, 8 nM and 1.2 μM for VEGF-R1, PDGF-Rβ and FGF-R1, respectively and has greatest potency against PDGFR autophosphorylation.

CP-673451 is a selective inhibitor of PDGFRα/β with IC50 of 10 nM/1 nM in cell-free assays, exhibits > 450-fold selectivity over other angiogenic receptors, has antiangiogenic and antitumor activity.

MK-2461 is a potent and multi-targeted inhibitor for c-Met with IC50 of 0.4-2.5 nM, also inhibits FGFR1/2/3, KDR, TrkA/B, and Flt4 with IC50 of 65/39/50 nM, 44 nM, 46/61 nM, and 78 nM respectively.